Joshua Disbrow, CEO of Aytu Biopharma, discusses the fiscal 2024 Q4 earnings call with positive results. Focus on Rx business growth, pediatric portfolio improvement, and leveraging RxConnect for future growth. Strategic initiatives in place for sustained revenue and profit growth.